Cytokinetics (NASDAQ: CYTK) EVP exercises options, sells 3,500 shares
Rhea-AI Filing Summary
CYTOKINETICS INC EVP Research & Development Fady Ibraham Malik exercised 3,500 non-qualified stock options at $7.80 per share on July 21, 2026, receiving 3,500 common shares and selling the same number at $80.59 per share. The transactions, conducted under a Rule 10b5-1 trading plan, left him holding 33,886 non-qualified stock options.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 3,500 shares ($255K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Malik Fady Ibraham
Role
EVP Research & Development
Sold
3,500 shs ($282K)
Approx. gross sale proceeds
$282K
Approx. exercise cost
$27K
Approx. pre-tax spread
$255K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (Right to Buy) | 3,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,500 | $7.80 | $27K |
| Sale | Common Stock | 3,500 | $80.59 | $282K |
Holdings After Transaction:
Non-Qualified Stock Option (Right to Buy) — 33,886 shares (Direct);
Common Stock — 153,902 shares (Direct)
Key Figures
Options exercised: 3,500 shares
Exercise price: $7.80 per share
Shares sold: 3,500 shares
+2 more
5 metrics
Options exercised
3,500 shares
Non-qualified stock options exercised on July 21, 2026
Exercise price
$7.80 per share
Conversion price for non-qualified stock option into common stock
Shares sold
3,500 shares
Common stock sale reported on July 21, 2026
Sale price
$80.59 per share
Reported per-share price for the common stock sale
Remaining options
33,886 options
Non-qualified stock options held after the reported exercise
Key Terms
Non-Qualified Stock Option (Right to Buy), Rule 10b5-1, derivative security
3 terms
Non-Qualified Stock Option (Right to Buy) financial
"Security titled "Non-Qualified Stock Option (Right to Buy)" was exercised"
Rule 10b5-1 regulatory
"Transactions were affirmed as conducted under a Rule 10b5-1 trading plan"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
derivative security financial
"Transaction code M described as "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Cytokinetics (CYTK) EVP Fady Malik report?
Fady Malik reported exercising 3,500 non-qualified stock options at $7.80 and selling 3,500 shares at $80.59. The activity occurred on July 21, 2026 and reflects an option exercise followed by a same-day share sale.
At what price were Cytokinetics (CYTK) stock options exercised in this Form 4?
The non-qualified stock options were exercised at $7.80 per share for 3,500 underlying shares. These options were then converted into common stock, which was subsequently sold at a much higher reported sale price per share.
Were the Cytokinetics (CYTK) insider transactions made under a Rule 10b5-1 plan?
Yes. The filing indicates the transactions were conducted under a Rule 10b5-1 trading plan. Such plans pre-establish trading parameters, so the timing of these trades is governed by the plan’s terms rather than discretionary decisions.
How many Cytokinetics (CYTK) stock options does the EVP hold after the reported transactions?
After exercising 3,500 options, Fady Malik continues to hold 33,886 non-qualified stock options. This figure reflects the remaining derivative securities reported as beneficially owned following the option exercise on July 21, 2026.
What type of securities were involved in the Cytokinetics (CYTK) Form 4 filing?
The filing involves non-qualified stock options and common stock. Malik exercised 3,500 non-qualified stock options, acquiring 3,500 common shares, and then sold those common shares in a separate reported transaction on the same date.